Topsun And Bayer Delay Record Deal On Black And White Cold Medicine
This article was originally published in PharmAsia News
Topsun Science and Technology has signed a supplementary agreement with Bayer to extend the transaction period for the latter to acquire Topsun's popular Black and White cold medicine. The new deadline for completing the deal is now postponed to June 30, 2008, eight months beyond the original contract. The supplementary agreement maintains the original transaction price but adds several new conditions for both parties. If the high-profile deal goes through, Black and White will break the acquisition record in China's drug industry with its price of 1.07 billion yuan. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?